Metabolic syndrome overview: Difference between revisions
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
[[Metabolic syndrome]] occurs in the presence of [[insulin]] resistance and accompanying [[obesity]]. It increases the risk for [[coronary heart disease]], [[diabetes, fatty liver, stroke and some | [[Metabolic syndrome]] occurs in the presence of [[insulin]] resistance and accompanying [[obesity]]. It increases the risk for [[coronary heart disease]], [[diabetes]], [[fatty liver]], [[stroke]] and some [[cancer]]s. It may manifests as [[hypertension]], [[hyperglycemia]], [[hypertriglyceridemia]], reduced high-density lipoprotein cholesterol and abdominal obesity. | ||
It affects a large number of people in a clustered fashion. In some studies, the [[prevalence]] in the USA is calculated as being up to 25% of the population. | It affects a large number of people in a clustered fashion. In some studies, the [[prevalence]] in the USA is calculated as being up to 25% of the population. | ||
Revision as of 22:34, 27 September 2011
|
Metabolic syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Metabolic syndrome overview On the Web |
|
American Roentgen Ray Society Images of Metabolic syndrome overview |
|
Risk calculators and risk factors for Metabolic syndrome overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.B.B.S. [2]
Overview
Metabolic syndrome occurs in the presence of insulin resistance and accompanying obesity. It increases the risk for coronary heart disease, diabetes, fatty liver, stroke and some cancers. It may manifests as hypertension, hyperglycemia, hypertriglyceridemia, reduced high-density lipoprotein cholesterol and abdominal obesity. It affects a large number of people in a clustered fashion. In some studies, the prevalence in the USA is calculated as being up to 25% of the population.